TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11098747

Group type: EXPERIMENTAL
Intervention: Endoscopic technique
Number of subjects: 29

Group type: COMPARATOR
Intervention: Two-tunnel technique
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Acute instability group
Number of subjects: 29

Group type: COMPARATOR
Intervention: Chronic instability group
Number of subjects: 29
Study: 8779380

Group type: EXPERIMENTAL
Intervention: Lignocaine 1.5% with 1 in 200,000 adrenaline (pH = 7.2)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lignocaine 1.5% with 1 in 200,000 adrenaline (pH = 4.2)
Number of subjects: 42
Study: 1514346

Group type: EXPERIMENTAL
Intervention: Prilocaine 0.5% and adrenaline 1:250,000 (Group 1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Prilocaine 0.5% and adrenaline 1:250,000 (Group 2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Plain prilocaine 0.5% (Group 3)
Number of subjects: 21
Study: 6390999

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30059487

Group type: EXPERIMENTAL
Intervention: Nomogram for survival prediction
Number of subjects: 376
Study: 26684437

Group type: EXPERIMENTAL
Intervention: Functional training
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 25554212

Group type: EXPERIMENTAL
Intervention: Amicus 3.11 apheresis separator
Number of subjects: 98

Group type: COMPARATOR
Intervention: Trima 5.22 apheresis separator
Number of subjects: 98
Study: 23948830

Group type: EXPERIMENTAL
Intervention: High-impact exercise
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Strengthening exercise
Number of subjects: 42

Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 42
Study: 20306017

Group type: EXPERIMENTAL
Intervention: Conventional training group including vibration (TGV)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Conventional training group (TG)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Wellness control group (CG)
Number of subjects: 151
Study: 19399934

Group type: EXPERIMENTAL
Intervention: 20 mg parecoxib infusion 30 min before induction of anesthesia and at 12 h after the first dose
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal saline infusion as placebo
Number of subjects: 70
Study: 17645463

Group type: EXPERIMENTAL
Intervention: 1-week furazolidone-based quadruple therapy (FABO1)
Number of subjects: 156

Group type: COMPARATOR
Intervention: 2-week furazolidone-based quadruple therapy (FABO2)
Number of subjects: 156
Study: 14679124

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day) concomitantly with EC chemotherapy (epirubicin 75 mg/m² + cyclophosphamide 600 mg/m² on day 1, every 21 days for four cycles)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Tamoxifen administered sequentially with EC chemotherapy
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Both treatment arms (CON and SEQ)
Number of subjects: 485
Study: 11294406

Group type: EXPERIMENTAL
Intervention: 4-hour laparoscopic dissection in a fresh cadaver
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no laparoscopic dissection)
Number of subjects: 28
Study: 9633980

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Dexamphetamine (DEX)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Parental report
Number of subjects: 102

Group type: COMPARATOR
Intervention: Side-effects
Number of subjects: 102
Study: 7889884

Group type: EXPERIMENTAL
Intervention: High boron intake (approximately 3.25 mg boron/2000 kcal/day)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Low boron intake (approximately 0.25 mg boron/2000 kcal/day)
Number of subjects: 3
Study: 3144581

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29847413

Group type: EXPERIMENTAL
Intervention: Tele‐PTM (telephone-based Progressive Tinnitus Management)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Tele‐PTM
Number of subjects: 205

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 205
Study: 28142391

Group type: EXPERIMENTAL
Intervention: Peer mentor
Number of subjects: 195

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 195
Study: 26297786

Group type: EXPERIMENTAL
Intervention: Group A: Pulmonary vein isolation (PVI) with adenosine challenge
Number of subjects: 152

Group type: COMPARATOR
Intervention: Group B: PVI with AF source ablation if AF did not terminate
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Group A: PVI
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Group B: AF source ablation
Number of subjects: 152

Group type: COMPARATOR
Intervention: Group B: PVI
Number of subjects: 152
Study: 23328566

Group type: EXPERIMENTAL
Intervention: TCFA at baseline
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Newly classified TCFA lesions at follow-up
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Minimum lumen area (MLA)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Percent necrotic core at MLA site
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Percent necrotic core over entire length of lesion
Number of subjects: 63
Study: 21791093

Group type: EXPERIMENTAL
Intervention: Injectable diacetylmorphine (or hydromorphone)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 232
Study: 18720053

Group type: EXPERIMENTAL
Intervention: Toothpaste
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Mouthrinse
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low air content slurry (LA)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High air content slurry (HA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 16957408

Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment
Number of subjects: 53
Study: 15087410

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study: 10611201

Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9106017

Group type: EXPERIMENTAL
Intervention: Azithromycin at 10 mg/kg once daily for 3 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clarithromycin at 15 mg/kg per day divided into two equal doses for 10 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Azithromycin and Clarithromycin
Number of subjects: 100
Study: 1539850

Group type: EXPERIMENTAL
Intervention: Halothane (approximately 0.6%)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Halothane (0.9%) with caudal analgesia
Number of subjects: 23

Group type: COMPARATOR
Intervention: Halothane (0.9%) with penile nerve block
Number of subjects: 23
Study: 2986422

Group type: EXPERIMENTAL
Intervention: 50, 100, and 200 micrograms ovine Corticotropin releasing factor (oCRF)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 50 and 100 micrograms human synthetic CRF
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 100 micrograms CRF dosage
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CRF test
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Corticoid therapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CRF administration
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: oCRF administration
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Endogenous CRF levels measured by oCRF radioimmunoassay
Number of subjects: 9
Study: 30067553

Group type: EXPERIMENTAL
Intervention: Higher pretreatment negative affectivity (NA)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Pretreatment positive affectivity (PA)
Number of subjects: 288
Study: 29248964

Group type: EXPERIMENTAL
Intervention: CVC insertion strategy (CVCi)
Number of subjects: 25348

Group type: EXPERIMENTAL
Intervention: Hand hygiene promotion strategy (HHi)
Number of subjects: 25348

Group type: EXPERIMENTAL
Intervention: Both interventions combined (COMBi)
Number of subjects: 25348

Group type: EXPERIMENTAL
Intervention: CVC insertion score
Number of subjects: 25348

Group type: EXPERIMENTAL
Intervention: Hand hygiene compliance
Number of subjects: 25348
Study: 26762123

Group type: EXPERIMENTAL
Intervention: Virtual reality exposure therapy (VRETp) combined with treatment as usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list condition receiving treatment as usual (TAU) only
Number of subjects: 0
Study: 24630505

Group type: EXPERIMENTAL
Intervention: Combined lamivudine/adefovir dipivoxil (Lam/Adv)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Entecavir 1mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 38
Study: 22440335

Group type: EXPERIMENTAL
Intervention: Experimental condition simulating testing anxiety
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (no stress induction)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Baseline levels of cortisol at session arrival
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Changes in cortisol
Number of subjects: 58
Study: 20185975

Group type: EXPERIMENTAL
Intervention: Hydrocortisone aceponate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednicarbate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical glucocorticoids (TGC)
Number of subjects: 0
Study: 18685353

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin/pregabalin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serotonin and noradrenaline-reuptake inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine patches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cannabinoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine or oxcarbazepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 0
Study: 15892796

Group type: EXPERIMENTAL
Intervention: New drugs for treating metastatic renal cancer
Number of subjects: 0
Study: 12194632

Group type: EXPERIMENTAL
Intervention: Airmax salbutamol (100-400 micrograms)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Salbutamol Ventolin (100-400 micrograms)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Salbutamol Diskhaler (100-400 micrograms)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Salbutamol Accuhaler (100-400 micrograms)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 10703303

Group type: EXPERIMENTAL
Intervention: One-to-one nurse/patient teaching
Number of subjects: 0

Group type: COMPARATOR
Intervention: One-to-one nurse/patient teaching plus take-home instructional chemotherapy video
Number of subjects: 0
Study: 8611831

Group type: EXPERIMENTAL
Intervention: Compliance therapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Non-specific counselling (Control)
Number of subjects: 47
Study: 2035504

Group type: EXPERIMENTAL
Intervention: Health Insurance Plan of Greater New York trial (intervention group)
Number of subjects: 0
Study: 7021262

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: ACC‐30 (ASA 375 mg; codeine phosphate 30 mg; caffeine citrate 30 mg)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 31769886

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg/d
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/d
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Metformin 2000 mg/d
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Metformin (all doses)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg/d)
Number of subjects: 361
Study: 29739848

Group type: EXPERIMENTAL
Intervention: Training needle device
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cotton tip applicator
Number of subjects: 23
Study: 28272840

Group type: EXPERIMENTAL
Intervention: Trauma-informed intervention addressing intimate partner violence and reproductive coercion
Number of subjects: 49
Study: 26320293

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (12.5 mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Atorvastatin (13.3 mg/day) + Ezetimibe (10 mg)
Number of subjects: 31
Study: 23420550

Group type: EXPERIMENTAL
Intervention: Communication skills‐building intervention
Number of subjects: 422

Group type: COMPARATOR
Intervention: Wellness control session
Number of subjects: 422
Study: 21139020

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) at 25 Gy
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) at 36 Gy
Number of subjects: 720
Study: 18331927

Group type: EXPERIMENTAL
Intervention: Onplant (Nobel Biocare)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Orthosystem implant (Institut Straumann AG)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Headgear
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Transpalatal bar
Number of subjects: 120
Study: 16594932

Group type: EXPERIMENTAL
Intervention: Lactic acid gel (LVG)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Metronidazole plus lactic acid gel
Number of subjects: 90

Group type: COMPARATOR
Intervention: Metronidazole alone
Number of subjects: 90
Study: 12477508

Group type: EXPERIMENTAL
Intervention: Continuous combined hormone replacement therapy (estradiol, 2 mg/d, and norethisterone acetate, 1 mg/d)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 9816618

Group type: EXPERIMENTAL
Intervention: SH U 508 A (Levovist)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Dynamic CT
Number of subjects: 588
Study: 7654045

Group type: COMPARATOR
Intervention: 5 FU alone (A)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 5 FU with levamisole (II)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 5 FU with folinic acid (B)
Number of subjects: 91
Study: 2709206

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotic therapy (Group I)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Nonantibiotic treatment (Group II)
Number of subjects: 96
Study: 1101757

Group type: EXPERIMENTAL
Intervention: Oral propranolol alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined propranolol and digoxin
Number of subjects: 20
Study: 6103766

Group type: EXPERIMENTAL
Intervention: Synthetic LHRH (HOE 471) administered intranasally for 4 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31091136

Group type: EXPERIMENTAL
Intervention: Cytogenetic Prognostic Index (PI) based on multivariable Cox model
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Cytogenetic abnormalities t(4;14) or del(17p)
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Cytogenetic PI
Number of subjects: 1635
Study: 29423508

Group type: EXPERIMENTAL
Intervention: Low postnatal serum levels of arachidonic acid (AA) (20:4 ω‐6)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low postnatal serum levels of arachidonic acid (AA) (20:4 ω‐6) and gestational age at birth
Number of subjects: 90
Study: 26529616

Group type: EXPERIMENTAL
Intervention: Estradiol variability
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Feelings of rejection in response to the laboratory stressor at month 8
Number of subjects: 52
Study: 25089310

Group type: EXPERIMENTAL
Intervention: Trained volunteer intervention (dietary and pharmacologic education, follow-up calls within 48 hours, and weekly calls for a month)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Trained volunteer intervention
Number of subjects: 137

Group type: COMPARATOR
Intervention: Standard care (control arm)
Number of subjects: 137
Study: 22828032

Group type: EXPERIMENTAL
Intervention: Bolus feeding (Group A) administered in 10 minutes followed by continuous feeding for 3 hours.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Continuous feeding (Group B) administered over 3 hours followed by bolus feeding in 10 minutes.
Number of subjects: 20
Study: 19348539

Group type: EXPERIMENTAL
Intervention: Negative mood induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive mood induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 0
Study: 17164234

Group type: EXPERIMENTAL
Intervention: Prescribed medications (average 3.7 prescribed medicines)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Over-the-counter (OTC) drugs (average 1.4 OTC drugs)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Determinants predicting polypharmacy: breathlessness, hypertension, dependency on instrumental activities of daily living, low subjective health, medication disagreement between doctors and patients
Number of subjects: 466
Study: 15616613

Group type: COMPARATOR
Intervention: Inborn delivery
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Outborn delivery
Number of subjects: 898
Study: 12167118

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 68

Group type: COMPARATOR
Intervention: Vasopressin + Omeprazole
Number of subjects: 68
Study: 10208393

Group type: EXPERIMENTAL
Intervention: Prestorage leukofiltered blood products (group B)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-filtered blood products (group A)
Number of subjects: 24
Study: 7829619

Group type: EXPERIMENTAL
Intervention: Testosterone (T)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 2196064

Group type: EXPERIMENTAL
Intervention: Sodium citrate (NaCit)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sodium chloride (NaCl)
Number of subjects: 8
Study: 350250

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 31993781

Group type: EXPERIMENTAL
Intervention: Ofatumumab (OFA) 1500 mg/1.73 m2
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal saline (Placebo)
Number of subjects: 13
Study: 31097860

Group type: EXPERIMENTAL
Intervention: 10 ml/kg Ringer's solution (R group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 10 ml/kg Voluven (V group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups (R group and V group)
Number of subjects: 70
Study: 27881555

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg daily plus P2Y12 inhibitor for 12 months (group 1)
Number of subjects: 2124

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily with DAPT stratification (group 2)
Number of subjects: 2124

Group type: COMPARATOR
Intervention: Dose-adjusted VKA daily with DAPT stratification (group 3)
Number of subjects: 2124
Study: 25905835

Group type: EXPERIMENTAL
Intervention: Mandated coverage for colorectal cancer screening
Number of subjects: 0
Study: 24188941

Group type: EXPERIMENTAL
Intervention: 1 g/kg body weight of honey daily for 4 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10 mg of loratadine daily for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Honey-flavored corn syrup as placebo
Number of subjects: 40
Study: 21331055

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 19282468

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/day)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m(2)/3 weeks)
Number of subjects: 490
Study: 17578320

Group type: EXPERIMENTAL
Intervention: nmAP (1.5 ml on Shenque acupoint once daily, placebo liquid 10 ml twice daily)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo paste on Shenque acupoint, Shanmai Jianpi Oral Liquid (10 ml twice daily)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo paste on Shenque acupoint, placebo liquid (10 ml twice daily)
Number of subjects: 180
Study: 15100617

Group type: EXPERIMENTAL
Intervention: 0.65 g/kg alcohol
Number of subjects: 34

Group type: COMPARATOR
Intervention: 0.0 g/kg (placebo)
Number of subjects: 34
Study: 11605096

Group type: EXPERIMENTAL
Intervention: Caffeine (2 mg/kg)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Caffeine-associated stimuli with information that the drink contained caffeine
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Information that the drink contained caffeine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Caffeine (0 mg/kg)
Number of subjects: 69
Study: 9532330

Group type: EXPERIMENTAL
Intervention: Meropenem (15‐20 mg/kg daily divided to 3 equal doses)
Number of subjects: 15
Study: 7521784

Group type: EXPERIMENTAL
Intervention: Controlled release hydromorphone every 12 hours
Number of subjects: 48

Group type: COMPARATOR
Intervention: Immediate release hydromorphone every 4 hours
Number of subjects: 48
Study: 2589661

Group type: EXPERIMENTAL
Intervention: Active airway humidification with MR450 Servo airway heater and humidifier set at 37 degrees C (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Passive airway humidification with Humid‐Vent Mini heat and moisture exchanger (n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No airway humidification and heating (control, n = 10)
Number of subjects: 30
Study: 1092294

Group type: EXPERIMENTAL
Intervention: 20 mg of deposteroid (methylprednisolone acetate) injected into the base of each tonsillar fossa
Number of subjects: 165

Group type: COMPARATOR
Intervention: Normal saline injected into the base of each tonsillar fossa
Number of subjects: 165
Study: 31934980

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no PRP)
Number of subjects: 40
Study: 30445937

Group type: EXPERIMENTAL
Intervention: Day care group (DG)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 257